# CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)

> **NCT03569579** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 20 (actual)

## Conditions studied

- Central Nervous System Diseases

## Interventions

- **DRUG:** Memantine Tab. 10mg
- **DRUG:** Memantine Tab. 10mg + Donepezil Tab. 10mg

## Key facts

- **NCT ID:** NCT03569579
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-16
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-06-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569579, "CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03569579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*